Registro de fonte primária

RelevanteApresentação em congresso

Perspective Therapeutics reports incremental Phase 1/2a data for bamzireotide navoxetan at NANETS 2026

Perspective Therapeutics presented additional analyses from its ongoing Phase 1/2a trial of bamzireotide navoxetan (VMT-α-NET) showing improved efficacy signals in the SSTR2+ GEP-NET subgroup (ORR 39%, DCR 95%, 18-month PFS 75%) compared to prior data and an approved radiotherapy. The company is incorporating an enrichment strategy into regulatory discussions and targets an End-of-Phase 2 meeting in Q1 2027 to enable Phase 3 initiation in 2027.

Fatos principais

Arquivado
5 de nov. de 2026, 12:00
Evento
Apresentação em congresso
Direção
Positivo
Fonte
SEC 8-K
Confiança
Com fonte
Calendário
Apresentação em congresso · 1 de nov. de 2026
DCR
95% (54/57) no subgrupo GEP-NET SSTR2+
ORR
39% (22/57) no subgrupo GEP-NET SSTR2+
PFS 18 meses
75% no subgrupo GEP-NET SSTR2+

Trecho da fonte

EX-99.1 2 catx-ex99_1.htm EX-99.1 EX-99.1 Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs • Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations • Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population • Bamzireotide continues to be well-tolerated • Targeting End-of-Phase 2 meeting in 1Q 2027 SEATTLE, November 5, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” t

SEC 8-K

Mais sobre este ativo

23 de out. de 2026
14:52
CATXPerspective Therapeutics

CATX reports positive Phase 1/2a interim data for VMT-α-NET at ESMO 2026

Alteração no registro do ensaioSEC 8-K
13 de out. de 2026
15:23
CATXPerspective Therapeutics

VMT-α-NET · NCT05636618 atualização do registo

Alteração no registro do ensaioClinicalTrials.gov
1 de out. de 2026
20:08
CATXPerspective Therapeutics

Perspective Therapeutics apresentará análise de dados do VMT-α-NET na ASCO 2026

Apresentação em congressoSEC 8-K
Perspective Therapeutics reports incremental Phase 1/2a data for bamzireotide navoxetan at NANETS 2026 | SimianX AI